Yoo J H, Huh D H, Choi J H, Shin W S, Kang M W, Kim C C, Kim D J
Bone Marrow Transplantation Center, College of Medicine, St. Mary's Hospital, Seoul, Korea.
Clin Infect Dis. 1997 Dec;25(6):1385-91. doi: 10.1086/516132.
We analyzed an outbreak of Escherichia coli bacteremia in eight patients with leukemia in a hematology-oncology unit from July to September 1994. The antibiograms and genotypic patterns of the isolates were different, thus suggesting that the outbreak did not originate from a single clone. However, all the isolates were resistant to quinolones, which led us to examine the microbiological records from 1992 to 1994. The incidence of quinolone-resistant E. coli bacteremia in the hematology-oncology unit ranged from 81.8% to 94.6% during this period. We then analyzed 36 more isolates recovered from late 1994 to 1995. Field inversion gel electrophoresis patterns of these isolates were also different. Analysis of the quinolone resistance determining region in gyrA revealed that all the isolates had a double mutation in gyrA. In conclusion, quinolone-resistant E. coli could be an emerging threat to neutropenic patients with leukemia who receive a quinolone prophylactically, and attention must be paid to this trend of resistance.
我们分析了1994年7月至9月在一家血液肿瘤科室发生的8例白血病患者的大肠杆菌菌血症暴发情况。分离株的抗菌谱和基因型模式各不相同,这表明此次暴发并非源自单一克隆。然而,所有分离株均对喹诺酮类耐药,这促使我们查阅1992年至1994年的微生物学记录。在此期间,该血液肿瘤科室喹诺酮耐药大肠杆菌菌血症的发生率在81.8%至94.6%之间。随后我们又分析了1994年末至1995年期间分离出的另外36株菌株。这些分离株的脉冲场凝胶电泳图谱也各不相同。对gyrA中喹诺酮耐药决定区的分析显示,所有分离株的gyrA均存在双突变。总之,喹诺酮耐药大肠杆菌可能会对接受喹诺酮预防性治疗的白血病中性粒细胞减少患者构成新的威胁,必须关注这种耐药趋势。